MARKET

INNMF

INNMF

Amplia Therapeutics Ltd
OTCMQB
0.100
NaN%
Closed 09:30 06/12 EDT
OPEN
--
PREV CLOSE
0.100
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.256
52 WEEK LOW
0.070
MARKET CAP
51.33M
P/E (TTM)
-7.4074
1D
5D
1M
3M
1Y
5Y
1D
Amplia lodges updated ASX corporate governance statement for 2026
TipRanks · 05/29 05:57
Amplia Therapeutics details ASX-aligned corporate governance framework
TipRanks · 05/29 03:58
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
TipRanks · 05/29 03:48
Amplia launches Phase 2b pancreatic cancer trial of narmafotinib with daily dosing
PUBT · 05/19 12:45
Amplia Therapeutics launches Phase 2b narmafotinib trial in advanced pancreatic cancer
PUBT · 05/18 22:58
Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan
PUBT · 05/12 06:53
Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance
TipRanks · 05/12 06:04
Amplia Therapeutics Adds 240,385 New Shares to ASX Listing
TipRanks · 05/12 05:51
More
About INNMF
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.

Webull offers Amplia Therapeutics Ltd stock information, including OTCMQB: INNMF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INNMF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INNMF stock methods without spending real money on the virtual paper trading platform.